<div id="readability-page-1"><div><p><span>ROCHE HOLDING AG </span><span>:</span></p><ul><li>RECEIVES FDA CLEARANCE WITH CLIA WAIVER AND CE MARK FOR ITS FIRST POINT-OF-CARE TEST FOR DIAGNOSING BORDETELLA INFECTIONS, INCLUDING WHOOPING COUGH (PERTUSSIS)</li><li>WHOOPING COUGH TEST RECEIVES FDA 510(K) CLEARANCE</li><li>TEST RECEIVES CLIA WAIVER AND CE IVDR CERTIFICATION</li></ul></div></div>

RHHBY

<p>ROCHE HOLDING AG :RECEIVES FDA CLEARANCE WITH CLIA WAIVER AND CE MARK FOR ITS FIRST POINT-OF-CARE TEST FOR DIAGNOSING BORDETELLA INFECTIONS, INCLUDING WHOOPING COUGH (PERTUSSIS) WHOOPING COUGH TEST RECEIVES FDA 510(K) CLEARANCETEST RECEIVES CLIA WAIVER AND CE IVDR CERTIFICATION</p>

Roche's Test For Diagnosing Whooping Cough Receives FDA Clearance